Press Releases

Adamis Pharmaceuticals Discusses 2017 Highlights and Business Update

SAN DIEGO, March 15, 2018 — Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today provided investors with an update concerning certain accomplishments for 2017 and accomplishments and goals for 2018.

2017 Highlights

As reflected in the company’s annual report on Form 10-K for year ending December 31, 2017, recently filed with the Securities and Exchange Commission, some of the company’s accomplishments during 2017 included the following:

  • New Drug Application (“NDA”) for Symjepi TM (epinephrine) Injection 0.3mg product, was approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of allergic reactions (Type I) including anaphylaxis.
  • Supplemental New Drug Application (“sNDA”) was submitted for the lower dose Symjepi TM (epinephrine) Injection 0.15mg product for patients weighing 33-65 pounds.
  • Investigational New Drug (“IND”) application was submitted to the FDA for a Naloxone injection product candidate, which uses the same approved injection device, for the treatment of opioid overdose.
  • The number of outstanding warrants was reduced through exercise transactions, which the company believes improved its balance sheet.
  • U.S. Compounding, Inc. subsidiary applied for a patent and began marketing a novel equine ulcer product for which the company believes there could be a significant market.

Early 2018 Highlights

Some of the company’s accomplishments during 2018 include the following:

  • In January, an IND application was submitted to the FDA for a beclomethasone HFA (APC-1000) product candidate and in February, the company received approval from the FDA to proceed with Phase 3 clinical studies.
  • In February, Adamis received correspondence from the FDA indicating that the agency had determined that the company’s sNDA for Symjepi ™ (epinephrine) Injection 0.15mg was sufficiently complete to permit a substantive review and indicated that no potential review issues were identified as of the date of the agency’s communication.
  • In March, Adamis presented human factors data for Symjepi ™ at the American Academy of Allergy Asthma and Immunology joint congress with the World Allergy Organization, and another human factors study was published in a peer-reviewed journal.

More on APC-1000

After the IND submission to the FDA, Adamis has recently received approval by the FDA to proceed to pivotal Phase 3 studies of APC-1000 in asthmatics. APC-1000 consists of a metered dose inhaler device containing an HFA (hydrofluoroalkane) inhaled corticosteroid called Beclomethasone, intended for the treatment of asthma. An ideal inhaled corticosteroid provides adequate lung exposure with limited systemic absorption of the drug. APC-1000 is being developed with the goal of demonstrating efficacy (lung function) and lower systemic absorption, thereby differentiating it from the current market leading inhaled corticosteroids. Following commencement of the studies, each asthmatic patient will be enrolled in the study for twelve weeks.

Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and cough. Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than an estimated 25 million people are known to have asthma. Based on industry sources, we estimate that the annual global sales of prescription steroid HFA and similar products are approximately $3 billion, of which we intend to target a smaller niche.

Inhaled corticosteroids play a major role in reducing the morbidity and mortality from asthma and also reduce the need for oral corticosteroids and their related systemic toxicity risks. According to the Expert Panel Report-3 on the Guidelines for the Diagnosis and Management of Asthma, inhaled corticosteroids, such as Beclomethasone, are recommended for all stages of persistent asthma in adults and children. However, inhaled corticosteroids are also known to have local and systemic adverse effects. The goal of the Phase 3 study of APC-1000 is mainly to demonstrate efficacy, but in addition, show an improved safety profile for asthmatic patients.

Dr. Carlo, commenting on the Phase 3 clinical studies of APC-1000, said, “We are pleased with the news of receiving approval to proceed to pivotal Phase 3 studies of APC-1000 by the FDA. We will continue to work with them and seek their guidance on the commercialization of what we believe is a needed product.” Dr. Ronald Moss, Chief Medical Officer of Adamis, added, “Our goal is to initiate the Phase 3 studies as soon as reasonably possible, during 2018. Having a cost-effective inhaled corticosteroid with a good safety profile would, we believe, greatly benefit asthmatic patients.”

Future Milestones

Some of the company’s goals for the 2018 year include the following:

  • Finalizing and announcing the commercialization strategy for Symjepi ™ (epinephrine) Injection 0.3mg;
  • FDA approval for Symjepi TM (epinephrine) Injection 0.15mg;
  • Initiate pivotal Phase 3 studies of APC-1000 in asthmatics;
  • Complete a “proof of concept” study with dry powder inhaler platform using fluticasone;
  • Filing an NDA for Naloxone injection;
  • Increase sales of compounded medications from our U.S. Compounding, Inc. subsidiary by at least 30%.

Dr. Carlo continued, “We remain committed to bringing Symjepi TM to market and are pleased with recent developments regarding our discussions with potential commercialization partners since our last press release pertaining to this topic. Once the commercial strategy is finalized, our focus will be advancing our other product candidates with the objective of increasing shareholder value. The entire Adamis team is working hard to achieve these goals during 2018.”

About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi™ (epinephrine) Injection 0.3mg, was approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ product pipeline includes HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.

The Company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.

Adamis Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning timing and outcome of finalizing the commercialization arrangements and strategy for its Symjepi ™ (epinephrine) Injection 0.3mg product; statements about strategies, objectives and our future goals and achievements; the company’s ability to commercialize its product and product candidates; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the safety and effectiveness of its products and product candidates; expectations and goals for future growth; current or planned clinical trials or research and development activities; anticipated commencement and completion dates for clinical trials; product development timelines; anticipated dates for commercial introduction of products; guidance regarding future periods; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the results of studies relating to Symjepi and user perceptions of Symjepi; the company’s beliefs concerning the safety and effectiveness of its products and product candidates; and other statements concerning our future operations and activities. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. In addition, many forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to support such activities and continue our operations and planned activities. As discussed in our filings with the Securities and Exchange Commission, we will require additional funding to continue operations, and there are no assurances that such funding will be available. Failure to timely obtain required funding would adversely affect and could delay or prevent our ability to realize the results contemplated by such forward looking statements. These statements are only predictions, are not guarantees, involve known and unknown risks, uncertainties and other factors, and concern matters that could subsequently differ materially from those described in this press release, which may cause Adamis’ actual results to be materially different from those contemplated by these forward-looking statements. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks, and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at

Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951

Primary Logo

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.